AGO4 RNA Endonuclease Activity (GO:0004521) — Hypothesis Deep Research Report

Target gene: AGO4 (Argonaute-4), Homo sapiens (NCBITaxon:9606) UniProt: Q9HCK5 · Term: GO:0004521 "RNA endonuclease activity" · Evidence: IBA (GO_REF:0000033) Focus type: function_assignment — does AGO4 directly have RNA-endonuclease (slicer) activity?

Summary

The IBA-propagated annotation of RNA endonuclease activity (GO:0004521) to human AGO4 is refuted / over-annotated and should be removed or negatively qualified. Argonaute "slicer" activity is a metal-dependent, RNase-H-like reaction carried out by the PIWI domain, and it strictly requires an intact catalytic tetrad of four residues (the DEDH tetrad: Asp-Glu-Asp-His) that coordinate two catalytic Mg²⁺ ions. Direct sequence analysis anchored on the experimentally validated human AGO2 catalytic residues (D597/E637/D669/H807) shows that human AGO4 has two of the four catalytic residues non-conservatively substituted: the catalytic aspartate (AGO2 Asp669) is a glycine (Gly671) in AGO4, and the catalytic histidine (AGO2 His807) is an arginine (Arg809). Loss of either residue is sufficient to abolish catalysis; AGO4 has lost both. AGO4 therefore cannot perform RNA-guided endonucleolytic cleavage.

This computational conclusion is independently corroborated by database curation and primary literature. UniProt annotates catalytic Mg²⁺-coordinating binding sites for AGO2 (597/669/807) and AGO3 (598/638/670/808) but none for AGO4 (or AGO1). The primary RNAi literature consistently establishes that among the four human paralogs only AGO2 is a constitutive slicer, with AGO3 added later as a conditional slicer; AGO1, AGO3, and AGO4 were classically defined as slicer-independent effectors, and non-AGO2 paralogs had to be engineered to become catalytically active. AGO4's genuine molecular role is as a slicer-independent miRNA effector that silences targets by recruiting the TNRC6/GW182 machinery, which drives translational repression and deadenylation-coupled mRNA decay — a mechanism that does not require endonucleolytic cleavage.

The single important caveat: the IBA annotation is technically defensible in the narrow phylogenetic sense that AGO4 descends from an ancestral Argonaute that had endonuclease activity and still adopts the PIWI fold. But GO annotation should reflect the actual molecular function of the specific gene product. By that standard AGO4 is a pseudo-catalytic, structurally slicer-dead paralog, and the annotation is a classic case of paralog over-annotation via phylogenetic propagation from the active AGO2 lineage.

Key Findings

Finding 1 — AGO4 lacks the intact DEDH catalytic tetrad required for slicer activity

The defining requirement for Argonaute endonuclease/slicer activity is a catalytic tetrad arranged within the RNase-H-like PIWI domain that together coordinate two catalytic Mg²⁺ ions and perform phosphodiester-bond hydrolysis of the target RNA. In human AGO2 — the one mammalian Argonaute unambiguously demonstrated to be an active slicer — these residues are Asp597, Glu637, Asp669, and His807 (the "DEDH" tetrad).

A global (Needleman–Wunsch) alignment of human AGO2 (Q9UKV8) against its three paralogs, anchored on these positions, gives:

The two critical AGO4 substitutions are visible in clean, ungapped alignment windows:

• Catalytic Asp → Gly: AGO2 IFYRDGVSE vs AGO4 IYYRGGVSE — the catalytic aspartate (D669) aligns to a glycine in AGO4.
• Catalytic His → Arg: AGO2 AYYAHLVAF vs AGO4 AYYARLVAF — the catalytic histidine (H807) aligns to an arginine in AGO4.

Both substitutions are non-conservative and hit residues individually essential for the two-metal-ion mechanism. The catalytic aspartate is a direct metal ligand; replacing it with side-chain-less glycine removes a required coordinating carboxylate. The catalytic histidine positions/activates the nucleophilic water and stabilizes the transition state; replacing it with arginine alters charge, geometry, and hydrogen-bonding capacity. AGO4 is 79.7% identical to AGO2 overall, so these are specific, functionally consequential changes at otherwise strongly conserved catalytic positions — not divergence in an unconserved region. The intact AGO3 tetrad, sitting in the same alignment as a positive family control, sharpens the contrast: the loss is AGO4-specific.

Finding 2 — UniProt independently annotates catalytic Mg²⁺-binding sites for AGO2/AGO3 but not for AGO4

As an orthogonal cross-check, the UniProt feature tables were compared across paralogs. UniProt annotates Mg²⁺-coordinating catalytic binding sites for AGO2 (positions 597, 669, 807) and AGO3 (positions 598, 638, 670, 808), consistent with those two proteins retaining the tetrad. UniProt annotates no catalytic binding sites for AGO4 (Q9HCK5) or AGO1. This database-level curation fully matches the de novo alignment and reflects the community consensus that AGO4 is not a metal-dependent nuclease.

Finding 3 — Primary literature consistently classifies AGO4 as slicer-independent

Three independent primary papers converge on the conclusion that AGO4 is not a catalytically active slicer:

• AGO2 is the sole constitutive mammalian slicer. Liu et al. established that of the mammalian Argonautes, "a single mammalian family member, Argonaute2, [is] responsible for messenger RNA cleavage activity" PMID: 15284456. This directly argues against endonuclease activity in AGO4.
• AGO4 explicitly described as slicer-independent. Park et al. state that "Of the four human Argonaute (AGO) paralogs, only AGO2 has been shown to have slicer activity. The others (AGO1, AGO3 and AGO4) have been thought to assemble with microRNAs to form slicer-independent effector complexes" PMID: 29040713. Critically, this paper adds AGO3 (not AGO4) as a newly demonstrated conditional slicer — AGO4 remains slicer-independent.
• Non-AGO2 paralogs must be engineered to become active. Hauptmann et al. "mutated inactive human Ago1 and Ago3 and generated catalytic Argonaute proteins" PMID: 23665583, showing that catalytic activity had to be restored by engineering — confirming the non-AGO2 paralogs are natively inactive. AGO4 was not among the rescued set.

Finding 4 — AGO4's actual effector mechanism is nuclease-independent silencing via TNRC6/GW182

AGO4's functional role in the miRNA pathway does not depend on endonuclease activity. Lazzaretti et al. showed that all four human Argonautes (AGO1–AGO4) recruit the GW182/TNRC6 family, and that the TNRC6 proteins execute silencing through their C-terminal silencing domains — independently of Argonaute catalysis — by promoting translational repression and mRNA deadenylation/decay PMID: 19383768. This provides a coherent, catalysis-free mechanistic account of AGO4-mediated silencing and removes any functional necessity for AGO4 to be a slicer.

Mechanistic Model / Interpretation

The Argonaute PIWI domain adopts an RNase-H-like fold; when the DEDH tetrad is intact it performs guide-directed, two-metal-ion endonucleolytic cleavage ("slicing") of a complementary target RNA. AGO4 retains the fold and can bind a miRNA guide and base-pair with targets, but its catalytic center is structurally incomplete:

       Guide RNA (miRNA)
             |
   5'........XXXXXXXXX........3'   target mRNA
             |||||||||
        [ PIWI domain ]
         D--E--D--H   <-- catalytic tetrad coordinates 2x Mg2+
             \  |  /
              Mg2+ Mg2+  --> phosphodiester hydrolysis (SLICING)

 AGO2:  D597 - E637 - D669 - H807   => INTACT  => active slicer
 AGO3:  D598 - E638 - D670 - H808   => INTACT  => conditional slicer
 AGO1:  D    - E    - D    - R805   => His->Arg => DEAD
 AGO4:  D589 - E629 - G671 - R809   => Asp->Gly + His->Arg => DEAD

Because the two-metal-ion mechanism requires the full complement of coordinating side chains, the AGO4 active site cannot assemble a competent catalytic center. AGO4 instead functions as a structurally slicer-dead effector:

   AGO4 (slicer-dead) + miRNA  ->  binds target mRNA
                     |
                 recruits TNRC6/GW182 (via GW-binding surface)
                     |
        TNRC6 C-terminal silencing domain
                     |
        translational repression + deadenylation/decay
                     |
              GENE SILENCING (no endonucleolytic cut)

This model reconciles all four findings: the missing catalytic residues (F1), the absent UniProt catalytic-site annotations (F2), the literature classification as slicer-independent (F3), and the demonstrated nuclease-independent silencing route (F4). The GO:0004521 annotation is best explained as an artifact of phylogenetic (IBA) propagation from an ancestral/AGO2 catalytic function, applied without accounting for the paralog-specific loss of catalytic residues in the AGO4 lineage.

Evidence Base / Evidence Matrix

GO Curation Implications (leads — require curator verification)

• Lead action: Do not retain GO:0004521 (RNA endonuclease activity) as a direct molecular-function annotation for AGO4. The IBA propagation is contradicted by AGO4's own sequence/structure and by UniProt, and should be removed or marked NOT for this gene. If the pipeline retains IBA statements, flag this one as an over-annotation contradicted by sequence and database evidence.
• Better-supported MF terms: RNA binding (GO:0003723) and/or miRNA binding (GO:0035198) — AGO4 binds small-RNA guides and recognizes targets by base pairing.
• Better-supported BP terms: gene silencing by miRNA (GO:0035195) / post-transcriptional gene silencing (GO:0016441) via translational repression and deadenylation — not slicing-based cleavage.
• Well-supported CC terms: RISC complex (GO:0016442) / cytoplasmic ribonucleoprotein granule (P-body).
• Preserve the key distinction: AGO4 is a non-catalytic RISC/effector subunit. Avoid defaulting to "protein binding" (GO:0005515) when RNA/miRNA-binding and silencing terms are supported.

Mechanistic Scope

The immediate molecular activity under test is RNA-guided phosphodiester-bond hydrolysis (slicing) by the PIWI (RNase-H-like) domain, requiring the DEDH tetrad plus two catalytic Mg²⁺. AGO4 lacks two of these residues → the direct activity is absent.

It is important to separate:

• Direct activity tested, absent: endonucleolytic RNA cleavage / slicing.
• Direct activity present (not the term under review): miRNA-guide binding and target-mRNA recognition.
• Downstream / pathway consequence (present): target-mRNA silencing — but executed via TNRC6/GW182-recruited translational repression and deadenylation-coupled decay, not by AGO4 catalysis.
• Not applicable: organismal loss-of-function phenotypes of AGO4 are downstream and cannot be used to infer catalytic activity.

Even where AGO4 contributes to "RNA degradation" at the pathway level, that degradation is performed by downstream deadenylases/decay machinery recruited via TNRC6 — not by AGO4 endonuclease chemistry.

Conflicts and Alternatives

• Paralog carry-over / frequency bias (most likely source): The IBA is driven by the well-characterized AGO2 slicer and the shared Argonaute/PIWI domain. Catalytic competence does not transfer to all paralogs; this is the classic paralog-overannotation pattern.
• AGO3 nuance: AGO3 does retain the tetrad and has guide-dependent slicer activity (PMID: 29040713) — so "all AGOs except AGO2 are inactive" is itself too strong. But AGO3's intact tetrad is exactly what AGO4 lacks, which sharpens (not weakens) the AGO4 conclusion.
• AGO1 comparison: AGO1 also loses the catalytic His (His→Arg805) and is likewise slicer-inactive (rescuable only by engineering, PMID: 23665583) — a consistent picture.
• Fold retention ≠ catalysis: AGO4 retains the PIWI/RNase-H fold and binds RNA, which may superficially justify an "endonuclease-fold" call. GO:0004521 asserts activity, not fold; the fold is present while the chemistry is not.
• In vitro vs in vivo: No primary study reports native AGO4 endonuclease activity; there is no positive experimental evidence to weigh against the refuting sequence/database evidence. No isoform/organism artifact was found that would rescue AGO4 activity.

Limitations and Knowledge Gaps

1. Sequence-based inference, not a direct AGO4 enzyme assay. Checked: alignment against validated AGO2 residues + UniProt cross-check. Why it matters: GO curation ideally rests on a direct assay. Resolution: a reconstituted in vitro slicer assay with purified guide-loaded AGO4 on a fully complementary target (as done for AGO3 in 29040713).
2. No structural active-site superposition was executed as provenance. Checked: residue identity/spacing in sequence only. Why it matters: an AlphaFold/PDB superposition on AGO2 would confirm geometric disruption and rule out compensatory rearrangement. Resolution: superpose AlphaFold Q9HCK5 onto AGO2 (e.g., PDB 4W5N/4F3T) and score catalytic-pocket geometry.
3. AGO4 not directly rescued in engineering studies. 23665583 restored Ago1/Ago3 but did not report a catalytic-AGO4 mutant, leaving open (though unlikely) additional catalysis-blocking features beyond the tetrad. Resolution: engineer AGO4 back-mutations (Gly671→Asp, Arg809→His) and assay.
4. Non-slicer nuclease activities not formally excluded. GO:0004521 is broader than "slicer." Checked: only slicer-relevant residues. Why it matters: AGO4 could in principle have a distinct non-canonical RNA-cleaving activity. Resolution: biochemical nuclease screen. No literature supports any such activity for AGO4.
5. Nuclear / non-canonical AGO4 roles (reported nuclear and interferon-related functions) were not exhaustively mined; none are expected to require intrinsic endonuclease activity.

Analytical limitations: pairwise NW alignment (not a full MSA); catalytic-residue identity taken from the established hAGO2 D597/E637/D669/H807 tetrad; database annotations are curator-level. None of these weaken the core conclusion, which rests on two non-conservative substitutions in clean, ungapped alignment blocks.

Proposed Follow-up Experiments / Actions

Discriminating experiments

1. Reconstituted slicer assay (definitive): purify guide-loaded human AGO4, incubate with a 5′-labeled fully complementary target RNA + Mg²⁺, assay for site-specific cleavage. Include AGO2 positive control and an AGO4 "restored-tetrad" (Gly671→Asp, Arg809→His) mutant. Expected: AGO2 cleaves, wild-type AGO4 does not.
2. Structural active-site superposition (fast, computational): align AlphaFold AGO4 (Q9HCK5) onto AGO2 catalytic PIWI structure; quantify absence/displacement of catalytic carboxylate and imidazole. Provenance-friendly and directly on-point.
3. Gain-of-function engineering: test whether the AGO4 double back-mutant (± N-terminal AGO2 elements) gains slicer activity, mirroring the AGO1/AGO3 engineering logic.
4. Comparative paralog panel: run AGO1/AGO2/AGO3/AGO4 side by side to demonstrate the AGO2(+)/AGO3(conditional)/AGO1,AGO4(–) pattern predicted by the tetrad analysis.

Curation actions (leads to verify)

• Remove / do-not-propagate GO:0004521 IBA on AGO4; consider a NOT GO:0004521 annotation to record the tested-and-absent activity.
• Add/retain better-supported terms: MF GO:0003723 / GO:0035198; BP GO:0035195 / GO:0016441; CC GO:0016442.
• Candidate snippets to cite (verify verbatim):
• 29040713: "Of the four human Argonaute (AGO) paralogs, only AGO2 has been shown to have slicer activity. The others (AGO1, AGO3 and AGO4) have been thought to assemble with microRNAs to form slicer-independent effector complexes."
• 15284456: "a single mammalian family member, Argonaute2, being responsible for messenger RNA cleavage activity."
• 23665583: "we have mutated inactive human Ago1 and Ago3 and generated catalytic Argonaute proteins."

Conclusion

Human AGO4 does not have RNA endonuclease (slicer) activity. Its PIWI catalytic tetrad is disrupted at two of four positions (catalytic Asp669→Gly671 and His807→Arg809 relative to active AGO2 D-E-D-H), UniProt annotates no catalytic metal-binding sites for AGO4, and primary literature consistently classifies AGO4 as a slicer-independent miRNA effector that silences targets through TNRC6/GW182-mediated translational repression and mRNA decay. The GO:0004521 IBA annotation is a paralog over-annotation propagated from ancestral/AGO2 catalytic function and should be removed or NOT-qualified, with AGO4's molecular function better captured by RNA/miRNA-binding, RISC-component, and miRNA-mediated-silencing terms.